SG11201408173WA - Pyrimidinyl tyrosine kinase inhibitors - Google Patents
Pyrimidinyl tyrosine kinase inhibitorsInfo
- Publication number
- SG11201408173WA SG11201408173WA SG11201408173WA SG11201408173WA SG11201408173WA SG 11201408173W A SG11201408173W A SG 11201408173WA SG 11201408173W A SG11201408173W A SG 11201408173WA SG 11201408173W A SG11201408173W A SG 11201408173WA SG 11201408173W A SG11201408173W A SG 11201408173WA
- Authority
- SG
- Singapore
- Prior art keywords
- massachusetts
- international
- road
- boston
- biogen idec
- Prior art date
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 title 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 1
- 241000237502 Ostreidae Species 0.000 abstract 1
- -1 PYRIMIDINYL Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000020636 oyster Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date ^ ^ WO 2013/185084 A1 12 December 2013 (12.12.2013) WIPO I PCT (51) International Patent Classification: A01N 43/40 (2006.01) A61K31/445 (2006.01) A61K31/435 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/044800 7 June 2013 (07.06.2013) English English (30) Priority Data: 61/657,360 8 June 2012 (08.06.2012) US (71) Applicants: BIOGEN IDEC MA INC. [US/US]; 133 Bo ston Post Road, Weston, Massachusetts 02493 (US). SUN- ESIS PHARMACEUTICALS, INC. [US/US]; 395 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (72) Inventors: HOPKINS, Brian T.; 169 Washington Street, Apt. 13, Newton, Massachusetts 02458 (US). CONLON, Patrick; 20 Eaton Street, Wakefield, Massachusetts 01880 (US). CHAN, Timothy R .; 53 Bennington Street, Newton, Massachusetts 02458 (US). JENKINS, Tracy J.; 44 Vin cent Avenue, Belmont, Massachusetts 02478 (US). CAI, Xiongwei; c/o BIOGEN IDEC MA INC., 133 Boston Post Road, Weston, Massachusetts 02493 (US). HUMORA, Michael; c/o BIOGEN IDEC MA INC., 133 Boston Post Road, Weston, Massachusetts 02493 (US). SHI, Xianglin; c/o BIOGEN IDEC MA INC., 133 Boston Post Road, We ston, Massachusetts 02493 (US). MILLER, Ross A.; 3001 Hadley Road, Suite 1-4, South Plainfield, New Jersey 07080 (US). THOMPSON, Andrew; 3001 Hadley Road, Suite 1-4, South Plainfield, New Jersey 07080 (US). (74) Agents: REARICK, John P. et al.; Choate, Hall & Stew art LLP, Two International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) •t 00 o 00 i-H o CJ (54) Title: PYRIMIDINYL TYROSINE KINASE INHIBITORS (57) Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyr osine kinase and which exhibit desirable characteristics for the same.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657360P | 2012-06-08 | 2012-06-08 | |
| PCT/US2013/044800 WO2013185084A1 (en) | 2012-06-08 | 2013-06-07 | Pyrimidinyl tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408173WA true SG11201408173WA (en) | 2015-01-29 |
Family
ID=49712704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201708535UA SG10201708535UA (en) | 2012-06-08 | 2013-06-07 | Pyrimidinyl tyrosine kinase inhibitors |
| SG11201408173WA SG11201408173WA (en) | 2012-06-08 | 2013-06-07 | Pyrimidinyl tyrosine kinase inhibitors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201708535UA SG10201708535UA (en) | 2012-06-08 | 2013-06-07 | Pyrimidinyl tyrosine kinase inhibitors |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9394277B2 (en) |
| EP (3) | EP2858499B1 (en) |
| JP (6) | JP6214643B2 (en) |
| KR (4) | KR20220154850A (en) |
| CN (3) | CN113549055A (en) |
| AR (1) | AR091273A1 (en) |
| AU (5) | AU2013271407B2 (en) |
| BR (2) | BR112014030655B1 (en) |
| CA (2) | CA3108186A1 (en) |
| CY (1) | CY1120638T1 (en) |
| DK (1) | DK2858499T3 (en) |
| EA (2) | EA201790418A1 (en) |
| ES (2) | ES2834333T3 (en) |
| HR (1) | HRP20181294T1 (en) |
| HU (1) | HUE039897T2 (en) |
| IL (2) | IL235938B (en) |
| IN (1) | IN2014DN10576A (en) |
| LT (1) | LT2858499T (en) |
| MX (2) | MX363672B (en) |
| NZ (1) | NZ702715A (en) |
| PH (2) | PH12018501463B1 (en) |
| PL (1) | PL2858499T3 (en) |
| PT (1) | PT2858499T (en) |
| RS (1) | RS57978B1 (en) |
| SG (2) | SG10201708535UA (en) |
| SI (1) | SI2858499T1 (en) |
| SM (1) | SMT201800442T1 (en) |
| TW (3) | TWI792158B (en) |
| WO (1) | WO2013185084A1 (en) |
| ZA (1) | ZA201409255B (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8785440B2 (en) * | 2009-09-04 | 2014-07-22 | Biogen Idec Ma, Inc. | Bruton's tyrosine kinase inhibitors |
| WO2012058645A1 (en) | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| WO2013185082A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Inhibitors of bruton's tyrosine kinase |
| AR091273A1 (en) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | PYRIMIDINYL TIROSINE KINASE INHIBITORS |
| DK3080103T3 (en) * | 2013-12-11 | 2018-07-30 | Biogen Ma Inc | BIARYL COMPOUNDS USED FOR TREATING HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY |
| WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
| LT3209656T (en) | 2014-10-24 | 2020-07-27 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhibitors |
| CN110049976A (en) | 2016-07-21 | 2019-07-23 | 比奥根Ma公司 | The succinate form and composition of bruton's tyrosine kinase inhibitor |
| JP7331843B2 (en) | 2018-04-27 | 2023-08-23 | 小野薬品工業株式会社 | Preventive and/or therapeutic agent for autoimmune diseases containing a compound having Btk inhibitory activity as an active ingredient |
| US12109193B2 (en) | 2018-07-31 | 2024-10-08 | Loxo Oncology Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
| JP2022526713A (en) | 2019-03-21 | 2022-05-26 | オンクセオ | Dbait molecule in combination with a kinase inhibitor for the treatment of cancer |
| JP2023500906A (en) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | Methods of treating cancers with acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| WO2023081709A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Vecabrutinib for the treatment of graft-versus-host disease |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| AU2022409472A1 (en) | 2021-12-14 | 2024-06-27 | Crossfire Oncology Holding B.V. | Macrocyclic btk inhibitors |
| WO2024246287A1 (en) | 2023-06-02 | 2024-12-05 | Crossfire Oncology Holding B.V. | Medical use of a macrocyclic reversible btk inhibitor |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024256568A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Salt and crystal forms of a macrocyclic btk inhibitor |
| WO2024256574A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Process for preparing macrocyclic btk inhibitors |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1624A (en) * | 1840-06-10 | Cooking-stove | ||
| US4528138A (en) | 1984-06-20 | 1985-07-09 | E. R. Squibb & Sons, Inc. | 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| PA8474101A1 (en) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
| US6919178B2 (en) | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
| IL151552A0 (en) | 2000-03-17 | 2003-04-10 | Bristol Myers Squibb Pharma Co | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
| CA2412560C (en) | 2000-06-26 | 2008-12-30 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
| PE20020507A1 (en) * | 2000-10-17 | 2002-06-25 | Schering Corp | NON-IMIDAZOLE COMPOUNDS AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR |
| WO2003037271A2 (en) * | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| EP1442039A1 (en) | 2001-10-31 | 2004-08-04 | Bayer HealthCare AG | Pyrimido (4,5-b) indole derivatives |
| ES2295816T3 (en) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | ARILO AND HETEROARILO 1,2,3-TRISUSTITUTED DERIVATIVES AS METABOLISM MODULATORS, AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THE SAME, SUCH AS DIABETES AND HYPERGLUCEMIA. |
| WO2005037825A2 (en) | 2003-10-14 | 2005-04-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
| WO2006073419A2 (en) * | 2004-04-01 | 2006-07-13 | Gang Zheng | Lipoprotein nanoplatforms |
| EP1750727A2 (en) | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
| FR2870541B1 (en) | 2004-05-18 | 2006-07-14 | Proskelia Sas | ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR |
| AR050865A1 (en) | 2004-09-09 | 2006-11-29 | Sanofi Aventis | DERIVATIVES OF 2- MORFOLINO-4-PIRIMIDONA |
| MX337817B (en) * | 2004-11-04 | 2011-11-04 | Vertex Pharma | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES. |
| CA2589483C (en) | 2004-12-03 | 2013-10-29 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| JP5274842B2 (en) | 2004-12-28 | 2013-08-28 | エグゼリクシス， インコーポレイテッド | [1H-piperazo [3,4-d] pyrimidin-4-yl] -piperazine as a serine-threonine kinase modulator (p70S6K, Akt-1 and Akt-2) for the treatment of immune, inflammatory and proliferative disorders Or [1H-piperazo [3,4-d] pyrimidin-4-yl] -piperazine compounds |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
| US20060281700A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| HUE028987T2 (en) | 2005-11-01 | 2017-01-30 | Targegen Inc | BI-aryl-meta-pyrimidine inhibitors of kinases |
| KR20080081321A (en) * | 2005-12-21 | 2008-09-09 | 쉐링 코포레이션 | Combination of H3 antagonist / reverse agonist and appetite suppressant |
| WO2008005368A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
| JP2009544732A (en) | 2006-07-26 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | Inhibitors of undecaprenyl pyrophosphate synthase |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| WO2008033858A2 (en) | 2006-09-11 | 2008-03-20 | Cgi Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| ES2585902T3 (en) | 2006-09-22 | 2016-10-10 | Pharmacyclics Llc | Bruton tyrosine kinase inhibitors |
| CL2008000594A1 (en) * | 2007-03-02 | 2008-09-05 | Schering Corp | USE OF COMPOUNDS DERIVED FROM HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND OTHER ACTIVE AGENTS; AND ITS USE TO TREAT DIABETES, CORONARY ARTERIAL DISEASE BETWEEN OTHER DISEASES. |
| CN101730699A (en) | 2007-03-21 | 2010-06-09 | 百时美施贵宝公司 | Can be used for treating the condensed heterocyclic compouds of proliferative, allergy, autoimmunity and diseases associated with inflammation |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| WO2008150799A1 (en) | 2007-06-01 | 2008-12-11 | Smithkline Beecham Corporation | Imidazopyridine kinase inhibitors |
| KR101308803B1 (en) | 2008-02-05 | 2013-09-13 | 에프. 호프만-라 로슈 아게 | Novel pyridinones and pyridazinones |
| EP2283358B1 (en) | 2008-04-29 | 2015-04-22 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| CN102159214A (en) | 2008-07-16 | 2011-08-17 | 药品循环公司 | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
| WO2010068788A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
| NZ593096A (en) * | 2008-12-19 | 2012-11-30 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
| WO2010080712A2 (en) * | 2009-01-06 | 2010-07-15 | Dana Farber Cancer Institute | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| US9139597B2 (en) | 2009-05-25 | 2015-09-22 | Sandoz Ag | Method for the production of ceftobiprole medocaril |
| EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYARY INHIBITORS OF BTK |
| US8785440B2 (en) | 2009-09-04 | 2014-07-22 | Biogen Idec Ma, Inc. | Bruton's tyrosine kinase inhibitors |
| US8685880B2 (en) * | 2010-06-30 | 2014-04-01 | Chevron U.S.A. Inc. | On-site drying of aqueous salt for ionic liquid make-up |
| WO2012058645A1 (en) | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| AR091273A1 (en) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | PYRIMIDINYL TIROSINE KINASE INHIBITORS |
| WO2013185082A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Inhibitors of bruton's tyrosine kinase |
| ES2713196T3 (en) | 2013-12-11 | 2019-05-20 | Biogen Ma Inc | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| DK3080103T3 (en) | 2013-12-11 | 2018-07-30 | Biogen Ma Inc | BIARYL COMPOUNDS USED FOR TREATING HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY |
| US20170298446A1 (en) | 2014-10-03 | 2017-10-19 | Ohio State Innovation Foundation | Biomarkers of bruton tyrosine kinase inhibitor resistance |
| CN110049976A (en) * | 2016-07-21 | 2019-07-23 | 比奥根Ma公司 | The succinate form and composition of bruton's tyrosine kinase inhibitor |
-
2013
- 2013-06-05 AR ARP130101980 patent/AR091273A1/en not_active Application Discontinuation
- 2013-06-07 TW TW110102365A patent/TWI792158B/en not_active IP Right Cessation
- 2013-06-07 NZ NZ702715A patent/NZ702715A/en not_active IP Right Cessation
- 2013-06-07 CN CN202110783143.4A patent/CN113549055A/en active Pending
- 2013-06-07 EP EP13800042.7A patent/EP2858499B1/en active Active
- 2013-06-07 WO PCT/US2013/044800 patent/WO2013185084A1/en not_active Ceased
- 2013-06-07 TW TW106116775A patent/TWI719209B/en not_active IP Right Cessation
- 2013-06-07 PT PT13800042T patent/PT2858499T/en unknown
- 2013-06-07 HR HRP20181294TT patent/HRP20181294T1/en unknown
- 2013-06-07 TW TW102120447A patent/TWI592406B/en not_active IP Right Cessation
- 2013-06-07 BR BR112014030655-9A patent/BR112014030655B1/en not_active IP Right Cessation
- 2013-06-07 KR KR1020227039393A patent/KR20220154850A/en not_active Ceased
- 2013-06-07 EA EA201790418A patent/EA201790418A1/en unknown
- 2013-06-07 MX MX2014015044A patent/MX363672B/en unknown
- 2013-06-07 MX MX2019003618A patent/MX385593B/en unknown
- 2013-06-07 KR KR1020157000393A patent/KR102102587B1/en not_active Expired - Fee Related
- 2013-06-07 US US14/406,315 patent/US9394277B2/en active Active
- 2013-06-07 DK DK13800042.7T patent/DK2858499T3/en active
- 2013-06-07 SI SI201331130T patent/SI2858499T1/en unknown
- 2013-06-07 KR KR1020217017552A patent/KR102468430B1/en active Active
- 2013-06-07 BR BR122021002178-3A patent/BR122021002178B1/en active IP Right Grant
- 2013-06-07 SG SG10201708535UA patent/SG10201708535UA/en unknown
- 2013-06-07 EP EP18171833.9A patent/EP3385263B1/en not_active Not-in-force
- 2013-06-07 PH PH1/2018/501463A patent/PH12018501463B1/en unknown
- 2013-06-07 ES ES18171833T patent/ES2834333T3/en active Active
- 2013-06-07 KR KR1020207010675A patent/KR20200043497A/en not_active Ceased
- 2013-06-07 IN IN10576DEN2014 patent/IN2014DN10576A/en unknown
- 2013-06-07 EP EP20186539.1A patent/EP3753934A1/en not_active Withdrawn
- 2013-06-07 EA EA201492056A patent/EA027823B1/en unknown
- 2013-06-07 HU HUE13800042A patent/HUE039897T2/en unknown
- 2013-06-07 ES ES13800042.7T patent/ES2684268T3/en active Active
- 2013-06-07 CN CN201380036869.5A patent/CN104540385B/en not_active Expired - Fee Related
- 2013-06-07 AU AU2013271407A patent/AU2013271407B2/en not_active Ceased
- 2013-06-07 CA CA3108186A patent/CA3108186A1/en not_active Abandoned
- 2013-06-07 RS RS20180950A patent/RS57978B1/en unknown
- 2013-06-07 LT LTEP13800042.7T patent/LT2858499T/en unknown
- 2013-06-07 JP JP2015516256A patent/JP6214643B2/en not_active Expired - Fee Related
- 2013-06-07 PL PL13800042T patent/PL2858499T3/en unknown
- 2013-06-07 SG SG11201408173WA patent/SG11201408173WA/en unknown
- 2013-06-07 CN CN201810384098.3A patent/CN109305959B/en active Active
- 2013-06-07 CA CA2875799A patent/CA2875799C/en active Active
- 2013-06-08 SM SM20180442T patent/SMT201800442T1/en unknown
-
2014
- 2014-11-27 IL IL235938A patent/IL235938B/en active IP Right Grant
- 2014-12-03 PH PH12014502699A patent/PH12014502699B1/en unknown
- 2014-12-15 ZA ZA2014/09255A patent/ZA201409255B/en unknown
-
2016
- 2016-06-29 US US15/196,389 patent/US9944622B2/en active Active
-
2017
- 2017-03-07 AU AU2017201536A patent/AU2017201536B2/en not_active Ceased
- 2017-08-03 JP JP2017150480A patent/JP2017193583A/en not_active Withdrawn
-
2018
- 2018-03-05 US US15/911,546 patent/US10618887B2/en active Active
- 2018-08-16 CY CY181100861T patent/CY1120638T1/en unknown
-
2019
- 2019-02-04 JP JP2019017850A patent/JP2019077728A/en not_active Withdrawn
- 2019-05-17 AU AU2019203476A patent/AU2019203476B2/en not_active Ceased
-
2020
- 2020-02-27 US US16/802,959 patent/US20210017155A1/en not_active Abandoned
- 2020-10-11 IL IL277951A patent/IL277951A/en unknown
-
2021
- 2021-02-08 JP JP2021018128A patent/JP2021073299A/en active Pending
- 2021-02-08 JP JP2021018127A patent/JP2021073298A/en active Pending
- 2021-04-21 AU AU2021202412A patent/AU2021202412A1/en not_active Abandoned
-
2022
- 2022-08-08 US US17/883,202 patent/US20230174511A1/en not_active Abandoned
- 2022-11-25 AU AU2022275504A patent/AU2022275504A1/en not_active Abandoned
-
2023
- 2023-01-16 JP JP2023004462A patent/JP2023052415A/en active Pending
-
2024
- 2024-08-23 US US18/813,750 patent/US20240417389A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408173WA (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201902886SA (en) | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |